M-M-R®II vaccine—demonstrated efficacy
Subcutaneous Administration
Actor Portrayal
Help protect against measles, mumps, and rubella with high immune response rates starting after the first dose
In a clinical trial of 284a patients, M-M-R®II seroconversion rates were high after the first dose.
aClinical studies of 284 triple-seronegative children 11 months to 7 years of age, demonstrated that subcutaneously administered M-M-R®II is highly immunogenic. In these studies, a single injection of the vaccine induced measles hemagglutination-inhibition (HI) antibodies in 95%, mumps neutralizing antibodies in 96%, and rubella HI antibodies in 99% of susceptible individuals.
M-M-R®II immunization provides coverage that can last over 10 years
Based on data from a clinical study, neutralizing and ELISA antibodies to MMR viruses were still found years after primary vaccination.
Antibodies were detected 11–13 years after primary vaccination in:
| 95%–100% |
|
of individuals
against measles
|
| 74%–91% |
|
of individuals
against mumps
|
| 90%–100% |
|
of individuals
against rubella
|
IM Administration
IM Administration Study Design:
In an open label clinical trial (NCT00432523), 752 children 12 through 18 months of age received M-M-R®II either intramuscularly (n=374) or subcutaneously (n=378), concomitantly with VARIVAX® (Varicella Virus Vaccine Live). Antibody responses to measles, mumps, and rubella viruses were measured by ELISAs using sera obtained 6 weeks postvaccination. For anti-measles virus, anti-mumps virus, and anti-rubella virus, seroresponse rates were defined as the percentage of children seronegative at baseline who achieved antibody titers above the respective seroresponse threshold for each assay 6 weeks postvaccination. Seroresponse thresholds were defined as 255 mIU/mL, 10 EU/mL, and 10 IU/mL for anti-measles virus, anti-mumps virus, and anti-rubella virus antibodies, respectively. For each vaccine antigen, at least 89% of enrolled children were seronegative at baseline.
IM Administration Post Hoc Analysis:
In a post hoc analysis, seroresponse rates to mumps and rubella viruses were noninferior for the intramuscular group compared to the subcutaneous group (the lower bound of the 95% confidence interval for the difference in seroresponse rates [intramuscular group minus subcutaneous group] ≥-5%). While the seroresponse rate to measles virus narrowly missed meeting the post hoc criterion of -5% for noninferiority (lower bound of the 95% CI for the difference in seroresponse rate -5.28%), it met the pre-specified criterion using a -10% noninferiority margin. For measles, mumps, and rubella antigens, the lower bound of the 95% CI of the seroresponse rates was >90% after intramuscular administration.
Actual size not shown
Looking to stock M-M-R®II in your practice?
Simply register or log in to your account to get started.
Dosage and Administration
Discover the dosing regimen and administration of M-M-R®II.
ACIP Recommendations
Find out about the ACIP recommendations for MMR vaccinations in pediatric patients.1
Reference
Reference
Indications and Usage for M-M-R®II
- M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
- The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.
Selected Safety Information for M-M-R®II
- M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
- Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
- Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
- Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
- The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.
- The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.
Dosage and Administration
- FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.
- M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.
Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.
Indications and Usage for M-M-R®II
- M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
- The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.
M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps
M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older. The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.
Selected Safety Information for M-M-R®II
- M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
- Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
- Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
- Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
- The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.
- The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.
Dosage and Administration
- FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.
- M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.
Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.
M-M-R®II is contraindicated in certain individuals, including those with: a history of
M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those